MedPath

An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2
Completed
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Registration Number
NCT01835093
Lead Sponsor
Chiba University
Brief Summary

Accumulating evidence suggests a role of G protein-coupled inwardly-rectifying potassium (GIRK) channel in the pathology of excitement of nerve, and the medicine with the action (like the Tipepidine Hibenzate) is expected as a new curative medicine of Attention Deficit / Hyperactivity Disorder (AD/HD).

The purpose of this research is to confirm the effect by carrying out the additional dosage of the Tipepidine Hibenzate to the AD/HD patients.

If suggestion is obtained by this research about the effect on AD/HD of Tipepidine Hibenzate, it can contribute to development of the medical treatment of AD/HD.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
A single-arm studyTipepidine Hibenzate-
Primary Outcome Measures
NameTimeMethod
ADHD Rating Scale-IV (ADHD-RS) Japanese VersionChanges from baseline in ADHD-RS at 4-weeks

The ADHD Rating Scale-IV obtains parent ratings regarding the frequency of each ADHD symptom based on DSM-IV criteria.

The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items).

Secondary Outcome Measures
NameTimeMethod
Cognition using DN-CAS (Das-Naglieri Cognitive Assessment System) Japanese VersionChange from baseline in the scores of battery at 4-weeks

The DN-CAS is an assessment battery designed to evaluate cognitive processing. It was developed to integrate theoretical and applied areas of psychological knowledge using cognitive processing theory and tests designed to measure-Planning, Attention, Simultaneous, and Successive Processing (PASS)-in individuals ages 5-17.

This assessment facilitates mental health professionals in the identification of Attention-Deficit/Hyperactivity Disorder, Traumatic Brain Injury, learning disabilities, Mental Retardation, and giftedness.

Trial Locations

Locations (1)

Department of Psychiatry, Chiba University School of Medicine

🇯🇵

Chiba, Chuo-ku, Japan

© Copyright 2025. All Rights Reserved by MedPath